Active Biotech Stock: A Look at Mannkind Corp

Biotech-stocks-ILMN-BIIB-AMGN-640x360

Shares of MannKind Corp. have been on a wild ride over the past year. Most of this volatility is the result of emotionally-charged retail investors pushing the stock past realistic valuation levels. This stock serves as another glaring example as to why it’s generally a bad idea to follow the crowd when investing in biotech stocks.

MannKind Corp. (NASDAQ MNKD) is the latest cult biotech to go belly up and investors/gamblers should use it as a prime example as to why these types of stocks are in fact dangerous.

Since signing the long-awaited partnership to market its newly approved inhaled insulin product Afrezza about a week ago with Sanofi (NYSE SNY), MannKind shares have fallen approximately 40% from their former highs. What’s particularly informative about the nature of MannKind’s supporters is that they were claiming that the stock was ready to double-or perhaps even triple, following this news.

Biotech Stock News

MannKind Corporation (NASDAQ MNKD) signed a $925 million worldwide licensing agreement with Sanofi SA (ADR) (NYSE SNY) (EPA:SAN) on August 11. The French drugmaker already has five principal products in diabetes. However, its top-selling diabetes drug Lantus will lose patent protection next year. Lantus is sold in more than 120 countries, generating $7.6 billion in annual revenue.

MannKind released its second-quarter results on August 11. The company reported a net loss of 19 cents a share compared to Brinson Patrick’s forecast of 13 cents in Q2 losses. Operating expenses rose to $69.8 million, largely due to non-cash stock compensation of $30.5 million. MannKind spent $37.3 million on R&D activities. Brinson Patrick has now raised its full-year 2014 operating expense estimate from $174.4 million to $199.7 million.

Biotech News Video

Watch this video for more “Biotech” news.

Biotech Financial News

Sanofi will pay MannKind $150 million upfront, and the remaining $775 million will be paid in multiple milestones based on Afrezza sales between 2015 and 2025. Although the Stock does not look in a good shape, it would not be entirely prudent to stay completely away from the stock. To wait and watch might be the best option in the current situation.

Thanks for visiting the TechNews.org website. Be sure to catch all BioTech financial news, bookmark us and check all the videos and news articles regarding Biotech business news.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone